Executive Insights

How Biosimilar Companies Can Survive an Uncertain Future

In this Executive Insights, we ask L.E.K. Consulting Managing Directors Jonathan Kfoury and Ricardo Brau to share their perspectives on emerging biosimilar development and business strategies (as well as mistakes to avoid), and the market’s future.

Based on your understanding of current market players, which of the biosimilar archetypes do you expect to be most successful in the market, and why?

It is hard to anticipate which specific archetype will be most successful, but companies with strong and relevant biologics manufacturing, developing and commercialization capabilities will likely be best-positioned to achieve and sustain leadership in the biosimilars market. We have seen companies belonging to different archetypes (e.g., Celltrion, Pfizer/Hospira, Sandoz/Novartis and Amgen) become leaders in the early days of biosimilars. In the long term, we expect companies that are committed to biosimilars to win out. As the competitive pressures mount, continued investment to drive scale, sophistication and brand trust/equity could allow biosimilar machines and bio-powerhouses to differentiate themselves with healthcare practitioners, patients and payers while maintaining reasonable margins.

Do you see other archetypes emerging in the market today (or in the future)?

Generally not beyond the six archetypes noted in a recent article (see “The Players in the Biosimilar Market: 6 Archetypes”), although the early years of market formation (particularly in the U.S.) will go a long way toward informing what the mix of viable/successful archetypes will be over the mid to longer term. Different types of players will attempt to establish durable market positioning with their respective strengths (e.g., existing relationships with physicians, pricing, brand loyalty/trust, channel strength).

In fact, it is possible that the number of biosimilar archetypes will contract over time. We have seen several biosimilar players struggle with developing costs and timelines relative to expected returns, while companies like Merck KGaA/EMD are divesting their biosimilar capabilities. If the risk-reward ratio does not improve, the number of biosimilar players may shrink over time.

What biosimilar business strategies have you noted as being particularly effective in the U.S. and EU markets?

To date, biosimilar adoption in the U.S. and the EU has been driven by pricing. This is not surprising given the large costs associated with branded biologics like Remicade and others.
However, it is clear that hospitals, payers and government bodies are seeking substantial discounts in order to adopt biosimilars, although the discount threshold needed is indication- and geography-dependent and different for each stakeholder. As a high-level example, Remsima (Celltrion/Orion) provided an approximately 69% discount relative to Remicade in Norway and was able to quickly capture about 80% of the market. In contrast, Hospira/Pfizer launched Inflectra at an approximately 15% discount relative to Remicade in the U.S., but Johnson & Johnson recently reported a limited impact on the sales of its branded biologic.

**What are the biggest mistakes you’re seeing biosimilar companies making today?**

As anticipated, the majority of the focus for existing/emerging players is around the largest, mega-blockbuster molecules (e.g., adalimumab) losing exclusivity in the next few years, but there appears to be much less in development for the next one to two levels down of originator molecules. With the competition expected to be fierce among those largest molecules during coming years, it is becoming harder to see how newer biosimilar entrants pursuing these assets will be able to drive strong returns, especially if late to market (when prices have eroded). Competitors should be looking at not just the biggest targets by sales but also where they can leverage core/unique strengths to pursue molecules with less competition (e.g., due to manufacturing/formulation complexity, disease area focus) where they can drive an early-to-market/leading position and commensurate return profile.

**What concerns do these mistakes raise for you in terms of surviving in specific markets?**

A key concern is that with many companies having few tools to drive differentiation and/or competitive position, pricing and net economics will be the main levers and will potentially precipitate a reduction in prices, especially as more biosimilars for a given molecule become available. Particularly in the highest-value biosimilar markets of the U.S. and the EU, it’s important for biosimilar manufacturers to preserve net price to drive favorable molecule-level and portfolio economics. If net prices are not maintained at healthy levels, this will put a premium on being first to market, which in turn may lead companies to take risks in preclinical and clinical development to compress time-to-market timelines.

**Flash forward 10 years down the road. Companies are going to need to get creative to set their biosimilars apart from the others on the market. Besides price, what specific incentives will companies need to offer to stand out?**

Given the specialty nature of many biosimilars, the commercial support behind them will likely need to reflect biologic brands in order to remain competitive and differentiate between one another. This is likely to be more pronounced during the launch of the first few biosimilars for a given brand — especially while stakeholders become comfortable with biosimilars in general — and includes sales forces, patient assistance programs and reimbursement support, among others. In addition, offering enhanced or additional formulations (e.g., subcutaneous) and device technologies will be areas in which biosimilar manufacturers can differentiate to some extent. However, net economics to payers, patients and health systems are still expected to carry the day.

Ultimately, achieving interchangeability could be a major differentiator for biosimilar manufacturers. This would drive volumes and reduce the need for commercial activities. Although the FDA has provided guidance on the requirements to achieve interchangeability, these may vary across products. Nevertheless, several manufacturers are conducting studies to demonstrate that patient treatment is not impacted by switching between brands and biosimilars at any point during treatment.
About the Authors

Jonathan Kfoury is a Managing Director and Partner in L.E.K. Consulting’s San Francisco office, and a senior leader of L.E.K.’s West Coast Life Sciences team. Jonathan joined L.E.K. in 2006 and focuses on growth strategy and pipeline/commercial planning for biopharmaceutical and medical technology clients. Prior to joining L.E.K., Jonathan held R&D and strategic planning roles of increasing responsibility at biotech and specialty biopharmaceutical companies.

Ricardo Brau is a Managing Director and Partner in L.E.K. Consulting’s Boston office. He focuses on the biopharmaceutical and life sciences sector, and has experience across most therapeutic areas and industry segments, in both large and emerging biopharma companies. He advises clients on a range of critical issues, including corporate and business unit strategy, innovation, R&D portfolio management and commercial planning.

About L.E.K. Consulting

L.E.K. Consulting is a global management consulting firm that uses deep industry expertise and rigorous analysis to help business leaders achieve practical results with real impact. We are uncompromising in our approach to helping clients consistently make better decisions, deliver improved business performance and create greater shareholder returns. The firm advises and supports global companies that are leaders in their industries — including the largest private and public sector organizations, private equity firms and emerging entrepreneurial businesses. Founded in 1983, L.E.K. employs more than 1,200 professionals across the Americas, Asia-Pacific and Europe. For more information, go to www.lek.com.